Subungual splinter hemorrhages: A clinical window to inhibition of vascular endothelial growth factor receptors? [4]

Annals of Internal Medicine

Volumn 143, Issue 4, 2005, Pages 313-314

  Robert, Caroline ^a   Faivre, Sandrine ^a   Raymond, Eric ^a   Armand, Jean Pierre ^a   Escudier, Bernard ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; NAY 439006; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RAF PROTEIN; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

BLEEDING; CLINICAL FEATURE; CLINICAL TRIAL; DEPIGMENTATION; HUMAN; KIDNEY CARCINOMA; LETTER; NAIL BED; NAIL DISEASE; PRIORITY JOURNAL; SUBUNGUAL SPLINTER HEMORRHAGE; TREATMENT OUTCOME;

EID: 23644450752     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-143-4-200508160-00021     Document Type: Letter

References (5)

1. Robert C, Spatz A, Faivre S, Armand JP, Raymond E. Tyrosine kinase inhibition and grey hair [Letter]. Lancet. 2003;361:1056. [PMID: 12660081]
2. Young JB, Will EJ, Mulley GP. Splinter haemorrhages: facts and fiction. J R Coll Physicians Lond. 1988;22:240-3. [PMID: 3230540]
3. Mujic F, Lloyd M, Cuadrado MJ, Khamashta MA, Hughes GR. Prevalence and clinical significance of subungual splinter haemorrhages in patients with the antiphospholipid syndrome. Clin Exp Rheumatol. 1995;13:327-31. [PMID: 7554559]
4. Monk BE. The prevalence of splinter haemorrhages. Br J Dermatol. 1980;103:183-5. [PMID: 7426414]
5. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2004;22:3238-47. [PMID: 15310767]